Literature DB >> 18391984

FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.

A N Cornforth1, J S Davis, E Khanifar, K L Nastiuk, J J Krolewski.   

Abstract

Androgen-withdrawal-induced apoptosis (AWIA) is deregulated in androgen refractory prostate cancer. Androgens have been shown to positively regulate expression of the antiapoptotic FADD-like interleukin-1beta-converting enzyme (FLICE)-like inhibitory protein (FLIP), and reduced FLIP expression precedes apoptosis after androgen withdrawal. Here, we show that FLIP protein expression is downregulated in castrated rats, while in LNCaP cells, androgens regulate FLIP in a manner that is dependent on phosphoinositol-3-kinase (PI3K) and Akt signaling. Specifically, treatment of LNCaP cells with LY294002, or expression of either PTEN or a non-phosphorylatable form of FOXO3a (FOXO3aTM), downregulates FLIP protein and mRNA. Conversely, treatment with androgens in the absence of PI3/Akt signaling, or following expression of FOXO3aTM, leads to increased FLIP expression. A FOXO3a binding site was identified in the FLIP promoter and shown necessary for the combined effects of androgens and FOXO3a on FLIP transcription. FOXO3a binds the androgen receptor, suggesting that the transcriptional synergy depends on an interaction between these proteins. Finally, LNCaP cells are sensitized to TRAIL-induced apoptosis by PTEN or LY294002, and rescued by androgens. FOXO3aTM also sensitizes cells to androgen-inhibited TRAIL apoptosis. Androgen rescue was diminished when either FOXO3a or FLIP was reduced by siRNA. These data support a role for FOXO3a in AWIA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391984     DOI: 10.1038/onc.2008.80

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

Review 1.  The "O" class: crafting clinical care with FoxO transcription factors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 2.  Forkhead followed by disordered tail: The intrinsically disordered regions of FOXO3a.

Authors:  Feng Wang; Christopher B Marshall; Mitsuhiko Ikura
Journal:  Intrinsically Disord Proteins       Date:  2015-06-03

3.  FOXO3a: A Potential Target in Prostate Cancer.

Authors:  Sanjeev Shukla
Journal:  Austin J Urol       Date:  2014

Review 4.  Opportunities and challenges in combination gene cancer therapy.

Authors:  Kent L Nastiuk; John J Krolewski
Journal:  Adv Drug Deliv Rev       Date:  2015-12-23       Impact factor: 15.470

5.  Coordinated induction of cell survival signaling in the inflamed microenvironment of the prostate.

Authors:  David W McIlwain; Marloes Zoetemelk; Jason D Myers; Marshé T Edwards; Brandy M Snider; Travis J Jerde
Journal:  Prostate       Date:  2016-02-24       Impact factor: 4.104

Review 6.  A fork in the path: Developing therapeutic inroads with FoxO proteins.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Jul-Aug       Impact factor: 6.543

7.  Arsenic trioxide-induced growth arrest of breast cancer MCF-7 cells involving FOXO3a and IκB kinase β expression and localization.

Authors:  Wenlou Liu; Yusen Gong; Haili Li; Guan Jiang; Shining Zhan; Hong Liu; Yongping Wu
Journal:  Cancer Biother Radiopharm       Date:  2012-09-18       Impact factor: 3.099

8.  Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms.

Authors:  Diping Wang; Ji Lu; Donald J Tindall
Journal:  Cancer Lett       Date:  2013-02-09       Impact factor: 8.679

9.  Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Patrick A Mayes; Luv Patel; David T Dicker; Akshal S Patel; Nathan G Dolloff; Evangelos Messaris; Kimberly A Scata; Wenge Wang; Jun-Ying Zhou; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.